Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Objective measurement of cough in pulmonary fibrosis: a cohort study - ImpaCT.
Kebbe J, Hart SP, Kaner RJ, Kulkarni T, Wollin L, Coeck C, Vinisko R, Patel N, Wijsenbeek MS. Kebbe J, et al. Among authors: kaner rj. ERJ Open Res. 2024 Sep 30;10(5):00310-2024. doi: 10.1183/23120541.00310-2024. eCollection 2024 Sep. ERJ Open Res. 2024. PMID: 39351380 Free PMC article.
Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry.
Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H, Roman J, Newby LK, Flaherty KR, Vinisko R, Liu Y, Roy J, Schmid R, Strobel B, Hesslinger C, Leonard TB, Noth I, Belperio JA, Palmer SM; IPF-PRO Registry investigators. Todd JL, et al. Respir Res. 2019 Oct 22;20(1):227. doi: 10.1186/s12931-019-1190-z. Respir Res. 2019. PMID: 31640794 Free PMC article. Clinical Trial.
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Wells AU, et al. Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.
An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis.
Ford P, Kreuter M, Brown KK, Wuyts WA, Wijsenbeek M, Israël-Biet D, Hubbard R, Nathan SD, Nunes H, Penninckx B, Prasad N, Seghers I, Spagnolo P, Verbruggen N, Hirani N, Behr J, Kaner RJ, Maher TM. Ford P, et al. Among authors: kaner rj. ERJ Open Res. 2024 Jan 29;10(1):00636-2023. doi: 10.1183/23120541.00636-2023. eCollection 2024 Jan. ERJ Open Res. 2024. PMID: 38288082 Free PMC article.
Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry.
Snyder L, Neely ML, Hellkamp AS, O'Brien E, de Andrade J, Conoscenti CS, Leonard T, Bender S, Gulati M, Culver DA, Kaner RJ, Palmer S, Kim HJ; IPF-PRO™ Registry investigators. Snyder L, et al. Among authors: kaner rj. Respir Res. 2019 May 30;20(1):105. doi: 10.1186/s12931-019-1043-9. Respir Res. 2019. PMID: 31142314 Free PMC article.
Patient perspectives on knowledge gaps in hypersensitivity pneumonitis.
Varadarajan J, Edgar A, O'Beirne R, Paul TK, Krishnan JK, Kaner R, Safford MM, Aronson K. Varadarajan J, et al. BMJ Open Respir Res. 2024 Oct 22;11(1):e002487. doi: 10.1136/bmjresp-2024-002487. BMJ Open Respir Res. 2024. PMID: 39438082 Free PMC article.
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; INSTAGE Investigators. Kolb M, et al. N Engl J Med. 2018 Nov 1;379(18):1722-1731. doi: 10.1056/NEJMoa1811737. Epub 2018 Sep 15. N Engl J Med. 2018. PMID: 30220235 Clinical Trial.
Phenotypes and Trajectories of Tobacco-exposed Persons with Preserved Spirometry: Insights from Lung Volumes.
Arjomandi M, Zeng S, Barjaktarevic I, Bleecker ER, Bowler RP, Criner GJ, Comellas AP, Couper DJ, Curtis JL, Dransfield MT, Drummond MB, Fortis S, Han MK, Hansel NN, Hoffman EA, Kaner RJ, Kanner RE, Krishnan JA, Labaki W, Ortega VE, Peters SP, Rennard SI, Cooper CB, Tashkin DP, Paine R 3rd, Woodruff PG. Arjomandi M, et al. Among authors: kaner rj. Ann Am Thorac Soc. 2024 Nov 25. doi: 10.1513/AnnalsATS.202405-527OC. Online ahead of print. Ann Am Thorac Soc. 2024. PMID: 39586032
Associations of circulating matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases with clinically relevant outcomes in idiopathic pulmonary fibrosis: Data from the IPF-PRO Registry.
Amubieya O, Todd JL, Neely ML, Kaner RJ, Lasky JA, Namen A, Hesslinger C, Palmer SM, Weigt SS, Belperio JA. Amubieya O, et al. Among authors: kaner rj. PLoS One. 2024 Oct 17;19(10):e0312044. doi: 10.1371/journal.pone.0312044. eCollection 2024. PLoS One. 2024. PMID: 39418259 Free PMC article.
164 results